Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$1.45 USD
+0.04 (2.96%)
Updated Oct 2, 2024 03:59 PM ET
After-Market: $1.50 +0.05 (3.33%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CNTB 1.45 +0.04(2.96%)
Will CNTB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNTB
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CNTB
CNTB Stock Surges Over 5% Amid Strong Financial Performance
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
Week In Review: EpimAb Sells T-Cell Engager In $635m Deal
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Connect Biopharma reports 1H net income $7.6M vs. net loss ($30.5M) 1H last year